RATIONALE: The study of genetic modifiers in cystic fibrosis (CF) lung disease requires rigorous phenotyping. One type of genetic association study design compares polymorphisms in patients at extremes of phenotype, requiring accurate classification of pulmonary disease at varying ages. OBJECTIVE: To evaluate approaches to quantify severity of pulmonary disease and their ability to discriminate between patients with CF at the extremes of phenotype. METHODS: DeltaF508 homozygotes (n = 828) were initially classified as "severe" (approximate lowest quartile of FEV(1) (% pred) for age, 8-25 yr) or "mild" disease (highest quartile of FEV(1) for age, > or = 15 yr). FEV(1) measurements from the 5 yr before enrollment (total = 18,501 measurements; average 23 per subject) were analyzed with mixed models, and patient-specific estimates of FEV(1) (% pred) at ages 5, 10, 15, 20, and 25 yr and slope of FEV(1) versus age were examined for their ability to discriminate between groups using receiver operating characteristics (ROC) curve areas. RESULTS: Logistic regression of severity group on mixed model (empirical Bayes) estimates of intercept and slope of FEV(1) (% pred) versus age discriminated better than did classification using FEV(1) slope alone (ROC area = 0.995 vs. 0.821) and was equivalent to using estimated FEV(1) at 20 yr of age as a single discriminator. The estimated survival percentile from a joint survival/longitudinal model provided equally good classification (ROC area = 0.994). CONCLUSIONS: In CF, estimated FEV(1) (% pred) at 20 yr of age and the estimated survival percentile are useful indices of pulmonary disease severity.
RATIONALE: The study of genetic modifiers in cystic fibrosis (CF) lung disease requires rigorous phenotyping. One type of genetic association study design compares polymorphisms in patients at extremes of phenotype, requiring accurate classification of pulmonary disease at varying ages. OBJECTIVE: To evaluate approaches to quantify severity of pulmonary disease and their ability to discriminate between patients with CF at the extremes of phenotype. METHODS: DeltaF508 homozygotes (n = 828) were initially classified as "severe" (approximate lowest quartile of FEV(1) (% pred) for age, 8-25 yr) or "mild" disease (highest quartile of FEV(1) for age, > or = 15 yr). FEV(1) measurements from the 5 yr before enrollment (total = 18,501 measurements; average 23 per subject) were analyzed with mixed models, and patient-specific estimates of FEV(1) (% pred) at ages 5, 10, 15, 20, and 25 yr and slope of FEV(1) versus age were examined for their ability to discriminate between groups using receiver operating characteristics (ROC) curve areas. RESULTS: Logistic regression of severity group on mixed model (empirical Bayes) estimates of intercept and slope of FEV(1) (% pred) versus age discriminated better than did classification using FEV(1) slope alone (ROC area = 0.995 vs. 0.821) and was equivalent to using estimated FEV(1) at 20 yr of age as a single discriminator. The estimated survival percentile from a joint survival/longitudinal model provided equally good classification (ROC area = 0.994). CONCLUSIONS: In CF, estimated FEV(1) (% pred) at 20 yr of age and the estimated survival percentile are useful indices of pulmonary disease severity.
Authors: Mitchell L Drumm; Michael W Konstan; Mark D Schluchter; Allison Handler; Rhonda Pace; Fei Zou; Maimoona Zariwala; David Fargo; Airong Xu; John M Dunn; Rebecca J Darrah; Ruslan Dorfman; Andrew J Sandford; Mary Corey; Julian Zielenski; Peter Durie; Katrina Goddard; James R Yankaskas; Fred A Wright; Michael R Knowles Journal: N Engl J Med Date: 2005-10-06 Impact factor: 91.245
Authors: Michal Kulich; Margaret Rosenfeld; Jonathan Campbell; Richard Kronmal; Ron L Gibson; Christopher H Goss; Bonnie Ramsey Journal: Am J Respir Crit Care Med Date: 2005-06-23 Impact factor: 21.405
Authors: Rebecca Darrah; Rebecca Nelson; Elizabeth G Damato; Michael Decker; Anne Matthews; Craig A Hodges Journal: Biol Res Nurs Date: 2016-04-13 Impact factor: 2.522
Authors: Rebecca Darrah; Edward McKone; Clare O'Connor; Christine Rodgers; Alan Genatossio; Sharon McNamara; Ronald Gibson; J Stuart Elborn; Madeleine Ennis; Charles G Gallagher; Noor Kalsheker; Moira Aitken; Dawn Wiese; John Dunn; Paul Smith; Rhonda Pace; Douglas Londono; Katrina A B Goddard; Michael R Knowles; Mitchell L Drumm Journal: Physiol Genomics Date: 2009-12-22 Impact factor: 3.107
Authors: Jiangchao Zhao; Patrick D Schloss; Linda M Kalikin; Lisa A Carmody; Bridget K Foster; Joseph F Petrosino; James D Cavalcoli; Donald R VanDevanter; Susan Murray; Jun Z Li; Vincent B Young; John J LiPuma Journal: Proc Natl Acad Sci U S A Date: 2012-03-26 Impact factor: 11.205
Authors: Ruslan Dorfman; Andrew Sandford; Chelsea Taylor; Baisong Huang; Daisy Frangolias; Yongqian Wang; Richard Sang; Lilian Pereira; Lei Sun; Yves Berthiaume; Lap-Chee Tsui; Peter D Paré; Peter Durie; Mary Corey; Julian Zielenski Journal: J Clin Invest Date: 2008-03 Impact factor: 14.808
Authors: YuanYuan Gu; Isaac T W Harley; Lindsay B Henderson; Bruce J Aronow; Ilja Vietor; Lukas A Huber; John B Harley; Jeffrey R Kilpatrick; Carl D Langefeld; Adrienne H Williams; Anil G Jegga; Jing Chen; Marsha Wills-Karp; S Hasan Arshad; Susan L Ewart; Chloe L Thio; Leah M Flick; Marie-Dominique Filippi; H Leighton Grimes; Mitchell L Drumm; Garry R Cutting; Michael R Knowles; Christopher L Karp Journal: Nature Date: 2009-02-25 Impact factor: 49.962